Retroscreen Virology Group PLC Board Changes (3803E)
09 Avril 2014 - 8:01AM
UK Regulatory
TIDMRVG
RNS Number : 3803E
Retroscreen Virology Group PLC
09 April 2014
For immediate release 07.00: 9 April 2014
RETROSCREEN VIROLOGY GROUP PLC
("Retroscreen" or the "Company")
BOARD CHANGES
Retroscreen Virology Group plc (AIM: RVG), the pioneer of hVIVO
human challenge models of disease, is pleased to announce strategic
changes to its Board of Directors ("Board") as part of the
Company's ambitious growth strategy. Professor John Oxford, one of
the founders of the Company and Duncan Peyton, who represented a
pre-IPO investor the Northern Entrepreneurs Fund, are both retiring
as Directors by rotation at the Company's AGM on 21 May 2014 and
not seeking reappointment. In addition, Dr Trevor Nicholls, an
experienced Company Director with a strong track record in the
bioinformatics field, is being proposed at the Company's AGM to
join the Board as a Non-Executive Director.
Professor John Oxford has served on Retroscreen's Board for 25
years, having previously acted as President, Scientific Director
and founder of the Company. Professor Oxford was a pioneer in the
field of viral challenge models having led the Common Cold Unit in
the UK to test a genetically modified influenza B virus. In 2002,
he leveraged this experience in clinical challenge trials to set up
a viral challenge unit at Queen Mary and Westfield College, which
later became Retroscreen Limited prior to its AIM listing in
2012.
Duncan Peyton became a Non-Executive Director of the Company on
3 April 2012, having previously represented the Northern
Entrepreneurs Fund on the Board from its investment in October 2009
until Retroscreen's IPO in May 2012 when they exited. Duncan has
played a crucial role in transforming Retroscreen from an academic
spin-out to a commercial enterprise and guiding the Company through
its stock market listing.
The Company has proposed that Dr Trevor Nicholls joins the Board
as a Non-Executive Director. Trevor is a company director having
over 30 years' experience of building international businesses in
the life science industry, with a strong focus on genomics and
proteomics. In particular, he was previously Chairman of Oxford
Nanopore Technologies Limited, is currently Chairman of Avacta
Group plc and was the Chairman of Activiomics Limited prior to its
recent acquisition by Retroscreen. Trevor is also Chief Executive
Officer of CABI, a not-for-profit inter-governmental organisation
owned by 46 member countries worldwide. Prior to his current role
with CABI, he was Chief Commercial Officer for Affymetrix Inc with
accountability for global operations, delivering $330 million
revenue with 600 staff across 8 locations worldwide. His technology
knowledge and leadership will be invaluable as Retroscreen expands
its bioanalytical activities.
Kym Denny, Chief Executive Officer, commented, "Retroscreen is
actively broadening its capabilities to fully exploit its unique
hVIVO technology platform. The proposed Board changes will enable
us to deliver this broader vision. I would like to thank both
Professor John Oxford and Duncan Peyton for their vital
contributions in helping Retroscreen become a high growth,
publically listed company. I would also like to welcome Dr Trevor
Nicholls, who brings valuable bioanalytical and bioinformatics
experience to our Board as we continue to pioneer our hVIVO
platform in new and novel ways."
Dr Trevor Nicholls, aged 57, is a director/ partner or has been
a director/ partner of the following companies/ partnerships during
the previous five years:
Current
Activiomics Limited
Avacta Group plc
C.A.B. International Limited
Conidia Bioscience Limited
Chaise Cottages Management Company Limited
Previous
Oxford Nanopore Technologies Limited
Oxloc Limited
Sea Gardens (Hope Cove) Limited
Trevor Nicholls holds options over 26,540 ordinary shares of 5p
each in Retroscreen. He was awarded options by Activiomics Limited
prior to his appointment to the Board of Retroscreen. These options
were rolled over into Retroscreen options on similar terms
following Retroscreen's acquisition of Activiomics Limited on 3
March 2014.
The options have an exercise price of 101.63 pence each and are
fully vested.
Dr Nicholls does not hold any ordinary shares in the
Company.
Save for the information disclosed above there is no other
information to be disclosed on Dr Trevor Nicholls under Schedule
2(g) of the AIM Rules.
For further information please contact:
Retroscreen Virology Group plc +44 207 756 1300
Kym Denny (CEO)
Graham Yeatman (FD)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Notes to Editors:
Retroscreen Virology Group plc ("Retroscreen") is a rapidly
growing UK life sciences company pioneering a technology platform
called hVIVO which uses human models of disease involving healthy
volunteers to study new drugs and investigate disease in a safe,
controlled environment.
Retroscreen has established itself as the world leader in this
field through the provision of clinical services to third party
study sponsors. To date, the Company has conducted over 35 clinical
studies, involving more than 1600 volunteers for a range of leading
industry, governmental and academic clients.
However, Retroscreen's hVIVO platform has a much wider
application in helping to understand illness because the Company
believes that the best way to understand human disease is by
studying it in humans, not laboratory models.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOASSFFUAFLSELL
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024